Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands h5n1 cross-clade neutralization

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Khurana, Surender ^a   Coyle, Elizabeth M ^a   Manischewitz, Jody ^a   King, Lisa R ^a   Ishioka, Glenn ^b   Alexander, Jeff ^b   Smith, Jon ^b   Gurwith, Marc ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b PaxVax ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; PLACEBO; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADENOVIRIDAE; ADENOVIRUS 4 H5N1; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; CLADISTICS; CONTROLLED STUDY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; SEROTYPE; SURFACE PLASMON RESONANCE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; ADMINISTRATION AND DOSAGE; BLOOD; CLASSIFICATION; CROSS REACTION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); PHASE 1 CLINICAL TRIAL (TOPIC); SECONDARY IMMUNIZATION;

ADENOVIRIDAE;

ADENOVIRUSES, HUMAN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; CLINICAL TRIALS, PHASE I AS TOPIC; CROSS REACTIONS; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; VACCINES, SUBUNIT;

EID: 84922114587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115476     Document Type: Article

References (32)

1. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. The Lancet infectious diseases. 2011; 11:916-24. doi: 10.1016/S1473-3099(11)70240-7 PMID: 21975270
2. Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, et al. A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis. 2014.
3. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebocontrolled, phase 1 study. The Lancet infectious diseases. 2013; 13:238-50. doi: 10.1016/S1473-3099 (12)70345-6 PMID: 23369412
4. Khurana S. Verma N. Yewdell J.W. Hilbert A.K. Castellino F.et alMF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines Sci Transl Med.2011385ra4810.1126/scitranslmed.3002336PMID: 21632986
5. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999; 37:937-43. PMID: 10074505
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354:1343-51. PMID: 16571878
7. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis. 2011; 205:610-20. doi: 10.1093/infdis/jir791 PMID: 22207649
8. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol. 2010; 85:1246-56. doi: 10.1128/JVI.02107-10 PMID: 21084473
9. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE. 2010; 5:e11548. doi: 10.1371/journal.pone.0011548 PMID: 20634959
10. Verma S, Dimitrova M, Munjal A, Fontana J, Crevar CJ, et al. Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies. J Virol. 2012; 86:12283-93. doi: 10.1128/JVI.01596-12 PMID: 22951833
11. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, et al. Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus. Science Translational Medicine. 2010; 2:15ra5-ra5. doi: 10.1126/scitranslmed.3000624 PMID: 20371470
12. Khurana S, Frasca D, Blomberg B, Golding H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog. 2012; 8:e1002920. doi: 10.1371/journal.ppat.1002920 PMID: 23028320
13. Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis. 2013; 208:413-7. doi: 10.1093/infdis/jit178 PMID: 23633404
14. Natuk RJ, Davis AR, Chanda PK, Lubeck MD, Chengalvala M, et al. Adenovirus vectored vaccines. Dev Biol Stand. 1994; 82:71-7. PMID: 7958485
15. Natuk RJ, Wade MS, Chengalvala M, Murthy KK, Chanda PK, et al. Adenovirus as vector for HIV: efficacy and safety issues. Dev Biol Stand. 1995; 84:153-6. PMID: 7796948
16. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature medicine. 1997; 3:651-8. PMID: 9176492
17. Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk RJ, et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol. 1998; 72:1052-9. PMID: 9444999
18. Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989; 86:6763-7. PMID: 2570422
19. Jones PD, Ada GL. Persistence of influenza virus-specific antibody-secreting cells and B-cell memory after primary murine influenza virus infection. Cell Immunol. 1987; 109:53-64. PMID: 3498544
20. Jones PD, Ada GL. Influenza-specific antibody-secreting cells and B cell memory in the murine lung after immunization with wild-type, cold-adapted variant and inactivated influenza viruses. Vaccine. 1987; 5:244-8. PMID: 3499714
21. Hyland L, Sangster M, Sealy R, Coleclough C. Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol. 1994; 68:6083-6. PMID: 8057487
22. Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. Science. 2013; 341:1205-11. doi: 10.1126/science.1241146 PMID: 24031013
23. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med. 2011; 208:2599-606. doi: 10.1084/jem.20110740 PMID: 22162833
24. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011; 208:181-93. doi: 10.1084/jem.20101352 PMID: 21220454
25. Alam S, Knowlden ZA, Sangster MY, Sant AJ. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol. 2014; 88:314-24. doi: 10.1128/JVI.02077-13 PMID: 24155379
26. Alexander J, Bilsel P, del Guercio MF, Stewart S, Marinkovic-Petrovic A, et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine. 2010; 28:664-72. doi: 10.1016/j.vaccine.2009.10.103 PMID: 19895924
27. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE. 2009; 4:e4384. doi: 10.1371/journal.pone.0004384 PMID: 19197383
28. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, et al. Influenza vaccine immunology. Immunol Rev. 2011; 239:167-77. doi: 10.1111/j.1600-065X.2010.00974.x PMID: 21198671
29. Garcon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012; 11:349-66. doi: 10.1586/erv.11.192 PMID: 22380826
30. Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2010; 31:443-54. doi: 10.1007/s10875-010-9490-6 PMID: 21174144
31. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A. 2009; 106:3877-82. doi: 10.1073/pnas.0813390106 PMID: 19237568
32. Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A. 2013; 110:14330-5. doi: 10.1073/pnas.1311998110 PMID: 23940329